# Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT02021162** · — · COMPLETED · sponsor: **University at Buffalo** · enrollment: 50 (actual)

## Conditions studied

- Multiple Sclerosis
- Healthy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02021162
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-09
- **Final completion:** 2018-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021162, "Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02021162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*